Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhPro-UK in acute mild ischemic stroke
NCT05507645Phase 3Completed
- Sponsor
- Beijing Tiantan Hospital
- Start
- Nov 2022
- Primary completion
- Mar 2024
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of recombinant human prourokinase in ischemic stroke (2 arms), sponsored by Beijing Tiantan Hospital. Primary endpoint: modified Rankin Scale score ≤ 1 at 90 days. Started Nov 2022; status: completed.
02
Drugs
recombinant human prourokinase
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT05507645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05507645.